Immunogenicity of an AAV-based, room-temperature stable, single dose COVID-19 vaccine in mice and non-human primates
Zabaleta, N.; Dai, W.; Bhatt, U.; Chichester, J. A.; Estelien, R.; Sanmiguel, J.; Michalson, K. T.; Diop, C.; Maciorowski, D.; Qi, W.; Hudspeth, E.; Cucalon, A.; Dyer, C. D.; Pampena, M. B.; Knox, J. J.; LaRocque, R. C.; Charles, R. C.; Li, D.; Kim, M.; Sheridan, A.; Storm, N.; Johnson, R. I.; Feldman, J.; Hauser, B. M.; Ryan, A.; Kobayashi, D. T.; Chauhan, R.; McGlynn, M.; Ryan, E. T.; Schmidt, A. G.; Price, B.; Honko, A.; Griffiths, A.; Yaghmour, S.; Hodge, R.; Betts, M. R.; Freeman, M. W.; Wilson, J. M.; Vandenberghe, L. H.
Show abstract
The SARS-CoV-2 pandemic has affected more than 70 million people worldwide and resulted in over 1.5 million deaths. A broad deployment of effective immunization campaigns to achieve population immunity at global scale will depend on the biological and logistical attributes of the vaccine. Here, two adeno-associated viral (AAV)-based vaccine candidates demonstrate potent immunogenicity in mouse and nonhuman primates following a single injection. Peak neutralizing antibody titers remain sustained at 5 months and are complemented by functional memory T-cells responses. The AAVrh32.33 capsid of the AAVCOVID vaccine is an engineered AAV to which no relevant pre-existing immunity exists in humans. Moreover, the vaccine is stable at room temperature for at least one month and is produced at high yields using established commercial manufacturing processes in the gene therapy industry. Thus, this methodology holds as a very promising single dose, thermostable vaccine platform well-suited to address emerging pathogens on a global scale.
Matching journals
The top 6 journals account for 50% of the predicted probability mass.
Similar papers in this journal
Similar papers in this journal
- A Single Dose of Self-Transcribing and Replicating RNA Based SARS-CoV-2 Vaccine Produces Protective Adaptive Immunity In Mice 96%
- Modular capsid decoration boosts adenovirus vaccine-induced humoral and cellular immunity against SARS-CoV-2 95%
- Immunogenicity of a new gorilla adenovirus vaccine candidate for COVID-19 94%
Similar papers in this journal
- GRAd-COV2 vaccine provides potent and durable immunity in randomised placebo-controlled phase 2 trial (COVITAR) 96%
- A single intranasal dose of chimpanzee adenovirus-vectored vaccine protects against SARS-CoV-2 infection in rhesus macaques 95%
- Deep immunological imprinting due to the ancestral spike in the current bivalent COVID-19 vaccine 94%
Similar papers in this journal
- Replicating bacterium-vectored vaccine expressing SARS-CoV-2 Membrane and Nucleocapsid proteins protects against severe COVID-19 disease in hamsters 96%
- Preclinical Characterization of the Omicron XBB.1.5-Adapted BNT162b2 COVID-19 Vaccine 96%
- Durability of DNA-LNP and mRNA-LNP Vaccine-Induced Immunity Against SARS-CoV-2 XBB.1.5 96%
Similar papers in this journal
- Breadth of SARS-CoV-2 Neutralization and Protection Induced by a Nanoparticle Vaccine 96%
- Omicron-specific mRNA vaccination alone and as a heterologous booster against SARS-CoV-2 96%
- Protective mucosal immunity against SARS-CoV-2 after heterologous systemic RNA-mucosal adenoviral vector immunization 96%
"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.